You are here

Article Text

Article menu
Download PDFPDF
Clinical pharmacology
Brexpiprazole toxicity in a paediatric patient
  1. Mohamad Bisher Akel1,
  2. Michelle E Condren1 and
  3. Sarah J Passmore2
  1. 1Pediatrics, University of Oklahoma School of Community Medicine, Tulsa, Oklahoma, USA
  2. 2Just Kids Pediatrics, Tulsa, Oklahoma, USA
  1. Correspondence to Mohamad Bisher Akel; mohamad-akel{at}ouhsc.edu

Abstract

Brexpiprazole is a relatively new drug that has no published research or applications within the paediatric population. Brexpiprazole targets multiple receptors and can manifest as multisystem symptoms when ingested in supratherapeutic quantities. In this report, we discuss the case of a child in early childhood who presented with delayed neurological and cardiac symptoms 24 hours after accidental ingestion of brexpiprazole. Due to delayed onset, this case highlights that a high index of suspicion and prolonged observation are necessary to appropriately manage brexpiprazole overdose or accidental ingestion.

  • Paediatrics (drugs and medicines)
  • Poisoning
  • Medical management
  • Toxicology
  • Drugs: psychiatry

https://doi.org/10.1136/bcr-2023-258561

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors MBA and MEC were responsible for drafting of the text, sourcing and editing of clinical images, investigation results, drawing of original diagrams and algorithms and critical revision for important intellectual content. SJP gave final approval of the manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.